AUAUniversity Podcast Series: Episode No. 71
GU Podcast (2020): Immune Checkpoint Inhibitors In RCC
Immune Checkpoint Inhibitors in RCC
At the conclusion of this activity, participants will be able to:
- Discuss the current immunotherapy options available for the treatment of RCC.
- Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.
- Identify and manage immune related adverse events.
This educational series is supported by independent educational grants from:
Bristol Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
UroGen Pharma, Inc.